Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.

NCT03515798 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT03515798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03515798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 29, 2018
Completion date
August 22, 2027
Enrollment
52 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory breast cancer